GLPwatch

The Transit Bipartition With the Use of a Metallic Anastomosis Clip and Circular Fundocorporeal Gastroplication

NCT07495020 · Recruiting

Last updated 2026-05-28

This clinical trial is testing a surgical procedure involving a metallic anastomosis clip and circular fundocorporeal gastroplication in adults with type 2 diabetes, obesity, or overweight to evaluate its effects on diabetes remission and complications like ulcers or leaks.

Status Recruiting Currently enrolling participants.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 90 people Planned (estimated).
Who can join Ages 18–65 · all sexes
Timeline Started 2026-04 · est. completion 2028-05
Where 1 site · Kazakhstan

What this study is testing ClinicalTrials.gov NCT07495020 ↗

Description as written by the study sponsor.

This study evaluates a new surgical device - the Metallic Anastomotic Clip (MAC) - for performing a laparoscopic bypass gastroenteroanastomosis with entero-enteric anastomosis (transit bipartition / "dual-path" procedure) in patients with type 2 diabetes mellitus (T2DM) who have overweight or Class I obesity (BMI 25-34.9 kg/m²). Currently, most bariatric and metabolic surgery procedures are only approved for patients with a BMI above 35 kg/m². However, many T2DM patients have BMI less 34.9 kg/m2 and cannot access surgical treatment under existing national guidelines. The transit bipartition procedure addresses this gap by creating a second food pathway from the stomach to the ileum while preserving normal duodenal digestion - producing a strong incretin (GLP-1) effect similar to GLP-1 receptor agonists (e.g., semaglutide), without causing excessive weight loss or requiring lifelong vitamin supplementation. The MAC is a novel compression anastomotic device designed to replace conventional hand-sewn or stapled anastomoses, potentially reducing complications such as anastomotic leak, bleeding, marginal ulcers, and strictures, while also lowering operative costs. Participants will be randomised into three groups. The study will assess metabolic outcomes (T2DM remission, glycaemic control), surgical safety, quality of life, and cost-effectiveness over a follow-up period of 2026-2027.

Treatments tested

Main thing measuredT2DM remission rate
SponsorThe Society of Bariatric and Metabolic Surgeons of Kazakhstan
Conditions studiedType 2 Diabetes Mellitus (T2DM), Obesity & Overweight, Marginal Ulcer (Peptic) or Erosion, Leakage, Anastomotic
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07495020 ↗